中科生物(01237.HK):附属若干出口至美国木制品倾销率及补贴率分别为44.6%及20.6%
中科生物(01237.HK)公布,於2020年12月29日商务部宣布对该产品之反倾销税调查及反补贴调查作出肯定之最终裁定,并确定存在44.6%至230.36%不等之倾销率及20.56%至252.29%不等之补贴率。
基於上述最终裁定,集团旗下全资附属公司漳平木村被裁定其若干出口至美国之木制品之加权平均倾销率及补贴率分别为44.6%及20.56%,商务部将指示美国海关和边境保护局将向集团产品之进口商收取费率合共为54.43%之保证金。
目前,美国国际贸易委员会计画在2021年2月11日或前後做出最终伤害裁定,如美国国际贸易委员会做出肯定的最终伤害裁定,商务部将向从中国进口之产品的发出反倾销和反补贴指令。如果美国国际贸易委员会对损害作出最终否定裁定,则调查将终止,并且不会下达任何指令。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.